Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × sapanisertib × Lymphoid × Clear all

Phase

Phase 2 3 Phase 1 2 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2 Thoracic 1 Lymphoid 1 Head & Neck 1 Endocrine 1 Dermatologic 1

Conditions

Interventions

Rituximab 145 Cyclophosphamide 141 fludarabine 70 Lenalidomide 64 Vincristine 62 fludarabine phosphate 58 Etoposide 51 Doxorubicin 49 Prednisone 48 venetoclax 46 Cytarabine 43 Dexamethasone 38 Peripheral Blood Stem Cell Transplantation 35 Filgrastim 35 Methotrexate 34 obinutuzumab 32 ibrutinib 32 Bendamustine Hydrochloride 31 Gemcitabine 28 Melphalan 26 Bortezomib 23 pembrolizumab 22 Radiotherapy 22 Alemtuzumab 22 Carboplatin 19 Whole-Body Irradiation 18 Nivolumab 18 Mycophenolic Acid 18 Busulfan 18 Tacrolimus 17

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02727777 2020-03-12

Phase II Study of TAK228 in Relapsed Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Terminated

4 enrolled 9 charts

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡